Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.

被引：1
|
作者：
Biran, Noa
Siegel, David Samuel DiCapua
Berdeja, Jesus G.
Raje, Noopur S.
Cornell, Robert F.
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy
Landgren, Carl Ola
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Huntsman Canc Inst, Salt Lake City, UT USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8022
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
    Fonseca, R.
    Panjabi, S.
    Campioni, M.
    Giannopoulou, A.
    Benedict, A.
    Houisse, I.
    Aggarwal, S.
    Jakubowiak, A.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
  • [22] Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Nam, Jennifer
    Severson, Erica
    Stephens, Leonor A.
    McDonnell, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd
    Karrison, Theodore
    Zonder, Jeffrey
    BLOOD, 2016, 128 (22)
  • [23] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Paulus, Aneel
    Alegria, Victoria R.
    Laplant, Betsy
    Moustafa, Muhamad Alhaj
    Chapin, Dustin
    Jackson, Keisha
    Jani, Prachi
    Ahmed, Salman
    Edwards, Brett
    Manna, Alak
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    BLOOD, 2019, 134
  • [24] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Phase I-b study of isatuximab plus carfilzomib in relapsed and refractory multiple myeloma (RRMM).
    Chari, Ajai
    Richter, Joshua Ryan
    Shah, Nina
    Wong, Sandy Wai Kuan
    Jagannath, Sundar
    Cho, Hearn J.
    Biran, Noa
    Wolf, Jeffrey
    Parekh, Samir S.
    Munster, Pamela N.
    Madduri, Deepu
    Campana, Frank
    Martin, Thomas G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [27] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [28] A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Hari, Parameswaran
    Schroeder, Mark A.
    Berenson, James R.
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Voorhees, Peter M.
    Fujii, Hisaki
    Yang, Zhao
    Galimi, Francesco
    Shain, Kenneth H.
    BLOOD, 2018, 132
  • [29] KRD (CARFILZOMIB PLUS LENALIDOMIDE PLUS DEXAMETHASONE) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CAMPANIA REGION: A ONE-YEAR SURVEY
    Palmieri, S.
    Rocco, S.
    Migliaccio, I.
    Cerchione, C.
    Catalano, L.
    Ferrara, K.
    Peluso, I.
    Monaco, G.
    Farina, G.
    Gagliardi, A.
    Barone, M.
    Esposito, D.
    Amico, V.
    Arcamone, M.
    Fontana, R.
    Sica, A.
    Pane, F.
    Ferrara, F.
    HAEMATOLOGICA, 2017, 102 : 126 - 126
  • [30] Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (KRd) vs. lenalidomide plus dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
    Jakubowiak, Andrzej J.
    Benedict, Agnes
    Panjabi, Sumeet
    Houisse, Ivan
    Campioni, Marco
    Giannopoulou, Andromachi
    Aggarwal, Sanjay
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345